Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

OncoMed doses first patient in phase I trial of OMP-305B83

Jan. 12, 2015

cCAM Biotherapeutics cleared to begin phase I trial of CM-24 for cancer

Jan. 8, 2015

Advaxis seeks FDA clearance to study ADXS-HER2 in HER2-expressing solid tumors

Jan. 8, 2015

FDA awards fast track designation to IMMU-132 for triple-negative breast cancer

Jan. 7, 2015

Promising data revealed on rindopipemut for the treatment of relapsed glioblastoma

Jan. 5, 2015

Met inhibition shows promising preclinical results for the treatment of nasopharyngeal carcinoma

Jan. 2, 2015

Data presented on a new chimeric antigen receptor targeting cancer

Dec. 30, 2014

FDA approves supplemental BLA for Gazyva

Dec. 30, 2014

Kite Pharma submits IND application for phase I/II trial of KTE-C19

Dec. 29, 2014

First U.S. approval granted for nivolumab injection for metastatic melanoma

Dec. 23, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...